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Abstract
Background: Deregulated signal transducer and activator of transcription 3 (STAT3) signaling has been well
documented in certain cancers. Alterations in specific negative regulators, such as protein inhibitor of activated
STAT3 (PIAS3), may contribute to cancer development.
Methods: The expression of total PIAS3 was determined in 100 paired cancerous and non-cancerous breast tissues
by immunoblotting and was statistically analyzed along with the clinicopathological characteristics and overall
survival of the patients. XTT, immunoblotting, and chromatin immunoprecipitation (Chip) were used to examine the
biological effect of PIAS3 in breast cancer cells.
Results: Hormone therapy failed to improve the overall survival in patients presenting with increased PIAS3
expression. Ectopic PIAS3 overexpression increased the proliferation and expression of cyclin D1 in estrogen
receptor (ER)-positive MCF-7 and T47D cells, but decreased those in ER-negative MDA-MB-231 and SKBR3 cells.
Furthermore, PIAS3 overexpression attenuated cytotoxicity of tamoxifen and increased proliferation and cyclin D1
expression in MCF-7 cells. PIAS3 also decreased the binding of itself on the cyclin D1 promoter and this decreased
binding was not affected by tamoxifen.
Conclusion: PIAS3 may serve as a biomarker for predicting hormone therapy stratification, although it is limited to
those breast cancer patients receiving hormone therapy
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Background
Deregulated Janus-activated kinase (JAK)/signal trans-
ducer and activator of transcription (STAT) signaling
has been closely associated with various human diseases.
In this pathway, STAT3 is the most recognized oncogene
and frequently is activated in human cancers [1]. Aber-
rations in a specific STAT3 regulator such as the protein
inhibitor of activated STAT3 (PIAS3) may also contrib-
ute to cancer development [2]. The PIAS3 transcript is
rarely detected in certain cancers such as mesotheliomas
[3] and lymphoma cells, and loss of PIAS3 expression is
responsible for constitutive STAT3 activation [4]. In
addition, ectopic expression of PIAS3 can suppress pros-
tate cancer cells through inducing apoptosis in vivo and
in vitro [5].
It is well documented that PIAS3 can inhibit the DNA-
binding activity of STAT3 and subsequently repress the
transcription activity of STAT3 [6]. Nevertheless, it is im-
portant to note that p-tyr705-STAT3 nuclear expression
positive breast cancer has a significantly improved short-
term (5-year) survival and long-term (20-year) survival
[7]. In addition, positive p-tyr705-STAT3 nuclear expres-
sion has been shown to be an independent prognostic
marker of better overall survival in node-negative breast
cancer using multivariate analyses. Other studies have
suggested that tyrosine 705 phosphorylation of STAT3 is a
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marker of good prognosis, at least in breast cancer [8, 9].
Thus, inhibition of STAT3 activity may specifically pro-
mote further development of breast cancer under certain
conditions. Interestingly, silencing the expression of the
PIAS3 gene significantly downregulates the expression of
estrogen receptor (ER) and its downstream targets in
MCF-7 cells [10]. In addition, PIAS3 acts as a SUMO-1
E3 ligase for ERα sumoylation [11]. ERα sumoylation is
strictly ligand (e.g., estrogen)-dependent in the presence of
PIAS3 and concomitant expression of PIAS3 with ERα
strongly activates estrogen-dependent transcription [11],
suggesting that PIAS3 may facilitate ER signaling. It is
controversial whether estrogen and ER are able to inhibit
STAT3 signaling [12]. Estrogen induces PIAS3 expression
and increases the physical association between PIAS3 and
STAT3 to block DNA binding and transactivation of
STAT3, suggesting that PIAS3 may serve as a co-regulator
that modulates crosstalk between ER and STAT3 [12].
These results suggest that interplay among ER, STAT3,
and PIAS3 may have a role in estrogen-dependent malig-
nancies such as breast cancer.
Constitutively activated STAT3 has been associated
with various malignancies [13–15]. Deregulation of its
negative regulatory system may play a role in breast can-
cer. In the present study, we explored whether the ex-
pression of total PIAS3 protein was aberrantly expressed
and whether these alterations contributed to breast can-
cer progression. We used immunoblotting to analyze the
levels of total PIAS3 in paired cancerous and adjacent
noncancerous breast tissues. We found that increased
total PIAS3 protein may predict poor prognosis. Our re-




A total of 100 patients with pathologically confirmed
breast cancer were included in this study. Paired cancer-
ous and noncancerous breast tissues were obtained from
the 100 patients who had undergone surgical treatment at
the Department of Surgery, Kaohsiung Medical University
Hospital (KMUH) from 2001 to 2009. None of the
patients had undergone radiotherapy or chemotherapy be-
fore surgery. The Institutional Review Board of Kaoshiung
Medical University Hospital approved the study (KMUH-
IRB-970222), and a written informed consent was ob-
tained from each patient. Specimens from patients were
frozen immediately in liquid N2, stored at −80 °C and/or
were routinely fixed in 10 % buffered formalin and embed-
ded in paraffin wax until further analysis. Chemotherapy
included six cycles of fluorouracil, epirubicin, and cyclo-
phosphamide or six cycles of docetaxel, epirubicin, and
cyclophosphamide. In accordance with the National
Comprehensive Cancer Network guidelines, chemotherapy
was mainly administered to lymph node-negative patients,
while hormonal therapy [usually tamoxifen (Tam) and ana-
strozole] was mainly administered to ER-positive patients.
Western blot analysis
Frozen specimens were ground in liquid N2 and dis-
solved in Triton X-100 lysis buffer. The cells were also
dissolved in the same lysis buffer. The extracts were cen-
trifuged at 13,200 rpm for 20 min at 4 °C. The protein
concentration in the supernatant was determined by Brad-
ford assay using the Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA, USA). Equal amounts of total protein
(~150 μg) were separated on 8 ~ 12 % sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis gels,
transferred to nitrocellulose membranes using a Semi-Dry
Transfer Cell (Bio-Rad), hybridized with primary antibody
for 2 h at room temperature (RT), identified with a sec-
ondary antibody for 1 h at RT, and exposed to Kodak film.
Rabbit polyclonal anti-PIAS3 (H-169), mouse monoclonal
anti-p-tyr705-STAT3 (B-7), anti-STAT3 (F-2), anti-ERα
(D-12), and anti-cyclin D1 (HD-11) were purchased from
Santa Cruz Biotechnology (Dallas, TX, USA).
Cell proliferation assay
MCF-7, T47D, MDA-MB-231, and SKBR3 breast cancer
cells were grown in six-well plates. The cells were at 60 %
confluence when they were transfected with the
PIAS3 expression plasmid using Lipofectamine™ 2000
reagent (Invitrogen, Carlsbad, CA, USA), and treated with
or without Tam (10−8M) (Sigma-Aldrich, St. Louis, MO,
USA). The cells were grown in Dulbecco’s modified
Eagle’s medium supplemented with 10 % fetal bovine
serum for 24 h and were harvested for XTT analysis.
Chromatin immunoprecipitation
The cells were fixed in 1 % formaldehyde for 10 min,
washed, and lysed in 500 μl cell lysis buffer (5 mM
HEPES, pH 8.0; 85 mM KCl; and 0.5 % NP-40) at 4 °C
for 10 min. The nuclei were released using a Dounce
homogenizer and lysed in 100 ~ 200 μl nuclei lysis buf-
fer (50 mM Tris–HCl, pH 8.0; 10 mM EDTA; and 1 %
SDS). The lysate was sonicated on ice, and the super-
natant was diluted 10-fold with dilution buffer (0.01 %
SDS; 1.1 % Triton X-100; 1.2 mM EDTA; 16.7 mM
Tris–HCl, pH 6.8; 167 mM NaCl). Anti-PIAS3 antibody
(1 μg, Santa Cruz Biotechnology) was added to 0.5 ~ 1.0
ml lysate and the sample was incubated at 4 °C over-
night. Immunocomplexes were then pulled down using
protein G-conjugated magnetic Dynabeads (Dynal Bio-
tech, Carlsbad, CA, USA). The beads were washed three
times with wash buffer (0.1 M sodium phosphate buffer,
pH 6.8; 0.1 % Tween-20), and the bound protein was
eluted twice with 30 μl 0.1 M citrate (pH 3.0). After-
wards, 240 μl extraction buffer (0.1 % SDS, 50 mM
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NaHCO3, 5 μl of 10 mg/ml RNase, 18 μl of 5 M NaCl)
was added to the pooled eluent and incubated at 65 °C
overnight. The reverted DNA was purified with a Mini-
prep spin column (Qiagen, Valencia, CA, USA) and
eluted in 50 μl of 10 mM Tris–HCl (pH 8.0). Polymerase
chain reaction (PCR) was performed with Taq DNA poly-
merase (Bioman, New Delhi, India) under the following
conditions: preheating at 95 °C for 2 min, followed by 35
cycles at 95 °C for 30 s, 56 °C for 30 s, and 72 °C for 45 s;
with a final extension at 72 °C for 8 min. The PCR prod-
ucts were visualized and analyzed by electrophoresis on 2
% agarose gels containing ethidium bromide. The primers
for the cyclin D1 gene promoter region were as follows:
5′-CGAACACCTATCGATTTTGCTAA-′3 and 5′-TTG
ACCAGTCGGTCCTTGCGG-3. Representative experi-
ments from three independent experiments are shown in
Fig. 3d.
Statistical analysis
Statistical analyses were performed using the SPSS 18.0
statistical package (SPSS, Inc., Chicago, IL, USA) for PC.
PIAS3 expression levels were normalized to the levels of
the corresponding β-actin protein. Image J software was
used to compare the expression levels of total PIAS3 in
breast cancer tissues and the adjacent noncancerous tis-
sues from the same patient after normalization with β-
actin. C > N was defined as the ratio of total PIAS3 to
the respective β-actin that was at least 50 % higher in
the cancerous tissue than that in the paired noncancer-
ous tissue. Similarly, C < N was defined as the ratio of
total PIAS3 protein to the respective β-actin in noncan-
cerous tissue that was at least 50 % higher than that in
the paired cancerous tissue. C = N was defined as less
than 50 % difference in the ratio of total PIAS3 protein
to the respective β-actin between the two paired tissues.
In the present study, the C = N (23 %) and C < N (39 %)
groups were categorized as one C ≦ N group (Fig. 1).
Groups of patients with different PIAS3 expression
levels were correlated with ER status, progesterone re-
ceptor (PR) status, human epidermal growth factor re-
ceptor 2 (Her2) status, tumor stage, tumor grade, lymph
node metastasis, and recurrence which were available in
the patients’ records, using Spearman’s rho coefficient
analysis and the chi-square test. Survival curves were
calculated using the Kaplan–Meier (K–M) method. Sig-
nificance was determined using the log rank test and a P
value of ≤ 0.05 was considered significant [16–18].
Results
Deregulated STAT3 signaling has been associated with
breast cancer [9, 19] and thus, alterations in PIAS3 may
also play a role in breast cancer. To determine the prog-
nostic significance of PIAS3 in patients with breast cancer,
we first used immunoblotting to analyze the expression
patterns in paired cancerous and adjacent noncancerous
breast tissues from the same patient. Total PIAS3 protein
decreased in 62 % of the 100 breast cancer tissues com-
pared with that in the adjacent noncancerous tissues
(Fig. 1). Nevertheless, no significant correlation was ob-
served between total PIAS3 protein expression levels and
the clinicopatholgical characteristics as determined by
X2 analysis (Table 1). Patients with decreased PIAS3 ex-
pression in tumor tissues tended to have advanced
tumor stage and positive node metastasis (Table 1). The
Kaplan–Meier (K-M) survival curves revealed that the
PIAS3 expression levels are not directly associated with
overall survival (Fig. 2a). Nevertheless, hormone therapy
only improved overall survival in patients who pre-
sented with decreased PIAS3 expression levels (Fig. 2b).
Radiotherapy or chemotherapy did not result in any im-
provement in the overall survival of patients with either
high or low PIAS3 expression (data not shown).
According to our clinical observations, PIAS3 expres-
sion appeared to interrupt the therapeutic effects of hor-
mone therapy mainly based on ER status. To determine
the potential roles of PIAS3 in breast cancer regarding ER
status, we transiently introduced the PIAS3 expression
plasmid into ER-positive MCF-7 and T47D cells as well as
ER-negative MDA-MB-231 and SKBR3 cells. Unexpect-
edly, ectopic PIAS3 overexpression increased proliferation
of MCF-7 and T47D cells but inhibited proliferation of
Fig. 1 Protein inhibitor of activated signal transducer and activator-
of transcription 3 (PIAS3) was detected in clinical breast cancer
specimens. Some examples of the immunoblotting results. Total
PIAS3 was determined by immunobotting in the breast cancer
tissues (C) compared with the adjacent noncancerous tissues (N).
The PIAS3 expression levels were normalized to the levels of the
corresponding β-actin protein. Image J software was used to
compare the expression levels of the total PIAS3 in the breast cancer
tissues and the adjacent noncancerous tissues from the same patient
after normalization with β-actin. C > N was defined as the ratio of
total PIAS3 to the respective β-actin that was at least 50 % higher in
the cancerous tissue than in the paired noncancerous tissue.
Similarly, C < N was defined as the ratio of the total PIAS3 to the
respective β-actin in the noncancerous tissue that was at least 50 %
higher than that in the paired cancerous tissue. C = N was defined
as less than 50 % difference in the ratio of the total PIAS3 to the
respective β-actin between the two paired tissues. M: MCF-7 cell line
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MDA-MB-231 and SKBR3 cells (Fig. 3a). Meanwhile,
PIAS3 increased cyclin D1 expression in MCF-7 and
T47D cells but inhibited the same in MDA-MB-231 and
SKBR3 cells (Fig. 3a), suggesting that different effects of
PIAS3 on breast cancer cells may be modulated by ER. Be-
cause of our clinical observations showed that increased
PIAS3 may reduce the overall survival of patients who
were mostly ER positive and were receiving Tam-based
hormone therapy, we further examined if Tam would
change the PIAS3-mediated proliferation and cyclin D
expression in ER-positive MCF-7 cells. We found that ec-
topic PIAS3 overexpression significantly attenuated the
cytotoxicity of Tam in ER-positive MCF-7 cells (Fig. 3b).
In addition, increased cyclin D1 expression upon ectopic
PIAS3 overexpression was not reversed by Tam but was
unexpectedly inhibited by 17β-estradiol (E2) (Fig. 3c). It
has been clearly demonstrated that PIAS3 can decrease
DNA binding of STAT3, as well as of itself, and inhibit the
transcription activity of STAT3. Accordingly, ectopic
PIAS3 overexpression decreased its binding to the con-
served and proven STAT3-binding site on the cyclin D1
promoter in MCF-7 cells (Fig. 3d). This decreased binding
of PIAS3 on the cyclin D1 promoter may explain why its
overexpression would lead to increased cyclin D1 expres-
sion. Consistently, Tam did not reverse this binding trend
and E2 retained binding of PIAS3 on the cyclin D1 pro-
moter after PIAS3 overexpression (Fig. 3d).
Discussion
Aberrant STAT3 signaling has been associated with breast
cancer. Therefore, it is important to understand the clinical
significance and underlying mechanisms of its downstream,
negative feedback regulator, PIAS3, in breast cancer. Our
results showed that the total PIAS3 level was mainly lower
in the breast cancer tissues than in the adjacent noncancer-
ous tissues, suggesting that a reduction of PIAS3 levels in
native breast tissues may be associated with breast cancer
development. Consistently, lower PIAS3 expression has also
been observed in gastric cancer and squamous cell carcin-
oma of the lung [20, 21]. Although the correlations did not
achieve significance, we found that decreased PIAS3 ex-
pression may contribute to advanced breast cancer devel-
opment including the advanced tumor staging and positive
node metastasis observed in our cases (Table 1). Notably,
Fig. 2 Kaplan-Meier analysis for overall survival of patients with breast cancer. a Survival curves of patients with high or low expression levels of
total protein inhibitor of the PIAS3 in paired cancerous and noncancerous breast tissues. b Survival curves of patients with different expression
levels of total PIAS3 after hormone therapy or no hormone therapy
Table 1 Correlation of total PIAS3 with clinicopathological
characteristics in breast cancer
Characteristics n (%) PIAS3 P
valueaC ≦ N C > N
Stage 0.064
I 30 (30.0) 14 16
II 44 (44.0) 28 16
III 26 (26.0) 20 6
Estrogen receptor status 0.852
Negative 38 (38.0) 24 14
Positive 62 (62.0) 38 24
Progesterone receptor status 0.843
Negative 54 (54.0) 33 21
Positive 46 (46.0) 29 17
Her2/Neu statusb 0.193
Negative 34 (35.1) 24 10
Positive 63 (64.9) 36 27
Lymph node metastasis status 0.071
Absent 49 (49.0) 26 23
Present 51 (51.0) 36 15
N, adjacent non-cancerous breast tissue; C, cancerous breast tissue; a, X2 test;
b, not determined in a small subset of the cases
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Fig. 3 Bioeffects of PIAS3 in breast cancer cells. a Ectopic PIAS3 overexpression increased the expression levels of cyclin D1 in estrogen receptor
(ER)-positive MCF-7 and T47D cells, but decreased those of cyclin D1 in ER-negative MDA-MB-231 and SKBR3 cells. b The XTT results revealed that
ectopic PIAS3 overexpression increased proliferation of ER-positive MCF-7 and T47D cells but inhibited proliferation of ER-negative MDA-MB-231
and SKBR3 cells. Ectopic PIAS3 overexpression attenuated the cytotoxicity of Tam to ER-positive MCF-7 cells. c Increased cyclin D1 expression
upon ectopic PIAS3 overexpression was not reversed by Tam, but was inhibited by 17β-estradiol (E2) in ER-positive MCF-7 cells. d Chromatin
immunoprecipitation revealed that ectopic PIAS3 overexpression decreased its binding to the conserved STAT3-binding element of the cyclin D1
promoter. Tam did not reverse the decreased trend of PIAS3 binding to the cyclin D1 promoter, while E2 increased PIAS3 binding to the cyclin D1
promoter after ectopic PIAS3 overexpression in ER-positive MCF-7 cells
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highly metastatic and aggressive ER-negative breast cancer
cell lines have relatively lower PIAS3 expression when com-
pared with ER-positive breast cancer cell lines (Additional
file 1: Figure S1).
Growing evidence has revealed that ectopic PIAS3
overexpression can inhibit cell proliferation and induc-
tion of apoptosis in cancer cells under certain conditions
[22, 23]. Our results showed that ectopic PIAS3 overex-
pression inhibited both proliferation (Fig. 3a) and migra-
tion (data not shown) of highly metastatic ER-negative
MDA-MB-231 cells. However, PIAS3 overexpression
stimulated cell growth of ER-positive MCF-7 and T47D
cells. Accordingly, PIAS3 increased the expression of
cyclin D1 in MCF-7 and T47D cells, but decreased the
same in MDA-MB-231 and SKBR3 cells. This suggests
that other co-regulators (i.e., ER) may change the func-
tions and activities of PIAS3 at least in breast cancer.
Induction of cyclin D1 gene transcription by ER plays an
important role in estrogen-mediated proliferation; however,
no classical estrogen response element is present in the cyc-
lin D1 promoter [24, 25]. It has also been demonstrated
that estrogen induces the expression of the PIAS3 gene and
increases the physical association between PIAS3 and
STAT3 [12]. Unexpectedly, ectopic PIAS3 overexpression
increased ligand (e.g., estrogen, E2)-independent cyclin D1
elevation in our study. We also found that ectopic PIAS3
overexpression promoted ligand-independent proliferation
of ER-positive breast cancer cells but inhibited cell growth
and cyclin D1 expression in ER-negative breast cancer cells.
We hypothesize that the difference of PIAS3-mediated ef-
fects on cell growth between the two types of cancer cell
lines is due to the presence of ER. It has been suggested ER
can interact with STAT3 to downregulate STAT3 signaling
such as cyclin D1 in our case [12]. We found that ectopic
PIAS3 overexpression increased the activation of
STAT3 in ER-positive MCF7 cells and decreased the
activation of STAT3 in MDA-MB-231 cells (Additional
file 2: Figure S2A). Accordingly, we found that several
downstream genes of STAT3 were downregulated in
MDA-MB-231 cells (Additional file 2: Figure S2B).
However, the expression levels of cyclin D1 and c-
myc, but not those of Bcl-2 and Mcl-1, were in-
creased upon PIAS3 overexpression in MCF7 cells, sug-
gesting that the PIAS3-mediated effects on ER-positive
breast cancer cells may be promoter-specific or ER-
related. In the present study, PIAS3 may interrupt or de-
crease the baseline inhibition of STAT3 signaling by ER in
ER-positive breast cancer cells. Accordingly, we observed
that cyclin D1 expression and proliferation were increased
by PIAS3 in ER-positive MCF-7 and T47D cells. In the ab-
sence of ER (e.g., MDA-MB-231 and SKBR3 cells), PIAS3
may inhibit STAT3 signaling directly or indirectly.
Interestingly, we also found that increased cyclin D1 ex-
pression after ectopic PIAS3 overexpression was not
reversed by Tam but was inhibited by E2. In addition, as
seen during clinical observations and in vitro studies, in-
creased PIAS3 may attenuate the therapeutic effects of
Tam-based hormone therapy in breast cancer patients as
well as the cytotoxicity of Tam to the breast cancer cells.
This observation is partially supported by a report that Tam
stimulates the growth of cyclin D1-overexpressing breast
cancer cells [12]. Furthermore, ectopic overexpression of
PIAS3 decreased its binding to the cyclin D1 promoter,
leading to an elevation of cyclin D1. Tam treatment did not
reverse this trend of reduced binding, but E2 treatment
maintained the binding of PIAS3 on the cyclin D1 pro-
moter after PIAS3 overexpression. Different conformational
changes between E2- and Tam-bound ER may contribute
to this effect. Taken together, these results suggest that
PIAS3 may be involved in Tam resistance because con-
comitant expression of ER and PIAS3 may promote cell
growth even when cells are treated with Tam. Furthermore,
our results revealed that hormone therapy improved overall
survival only in patients who presented with decreased or
low PIAS3 levels.
Conclusions
Our results revealed that PIAS3 may be a biomarker for
predicting hormone therapy stratification in patients with
breast cancer. Constitutively expressed/increased PIAS3
expression may attenuate the effectiveness of Tam-based
hormone therapy and thus predict poor overall survival.
Additional files
Additional file 1: Figure S1. Expression patterns of protein inhibitor
of activated signal transducers and activators of transcription 3 (PIAS3)
was detected in a panel of breast cancer cell lines. Total PIAS3 was
determined by immunobotting in various breast cancer cell lines and
one normal breast epithelial cell line. PIAS3 expression levels were
normalized to the levels of the corresponding β-actin protein. The Image
J software was used to compare the expression levels of total PIAS3. ER:
estrogen receptor; HME: human mammary epithelial cells. (PDF 73 kb)
Additional file 2: Figure S2. Effects of activated signal transducers and
activators of transcription 3 (PIAS3) on STAT3 signaling in breast cancer
cells. (A) Ectopic PIAS3 overexpression increased expression levels of
activated STAT3 (p-STAT3, p-tyr705-STAT3) in estrogen receptor (ER)-positive
MCF-7 cells, but decreased those of activated STAT3 in ER-negative
MDA-MB-231 cells. (B) Ectopic PIAS3 overexpression attenuated the
expression levels of STAT3 downstream genes including cyclin D1, c-myc,
Bcl-2, and Mcl-1 in ER-positive MDA-MB-231 cells. However, the expression
levels of cyclin D1 and c-myc, but those of Bcl-2 and Mcl-1, were
up-regulated in ER-positive breast cancer cells. (PDF 160 kb)
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